Please login to the form below
Intercept Pharmaceuticals
This page shows the latest Intercept Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.
Merck enters agreement with Hanmi for investigational NASH drug
Intercept Pharmaceuticals is awaiting a US Food and Drug Administration (FDA) review of its obeticholic acid drug Ocaliva in NASH after a number of delays, first in January and then again
Latest news
-
Genfit scraps phase 3 trial of experimental NASH drug
Another potential competitor – Intercept Pharmaceuticals – is still awaiting an FDA review of its obeticholic acid drug Ocaliva in NASH after a number of delays, first in January and then again in
-
FDA delays decision on Intercept's NASH drug by three months
Action date pushed back to 26 June. The US Food and Drug Administration (FDA) has pushed back the date on which it is due to decide whether to approve Intercept Pharmaceuticals’ ... additional information provided in response to FDA requests,”
-
Intercept gets EU nod for rare liver disease therapy
Ocaliva approved as a combination treatment for primary biliary cholangitis. Intercept Pharma now has approval for its Ocaliva drug for primary biliary cholangitis (PBC) therapy Ocaliva on both sides of the ... Intercept launched Ocaliva in the US
-
Gilead chalks up trial success for new NASH drug
The company is vying with rivals such as Allergan and Intercept Pharmaceuticals in its pursuit of the NASH market. ... Allergan has been building a pipeline of candidates through a series of bolt-on acquisitions including Akarna Therapeutics and Tobira
-
Takeda enlists GE's aid to tackle liver fibrosis epidemic
Takeda is playing catch-up in the liver fibrosis race, with rivals such as Gilead Sciences, Intercept Pharmaceuticals, Galectin Therapeutics and Genfit already having compounds in the clinic. ... Gilead's simtuzumab is in phase II testing in NASH, while
More from news
Approximately 1 fully matching, plus 5 partially matching documents found.
Latest appointments
-
Simon Doyle joins STEM
Doyle - who joins the group from Intercept Pharmaceuticals where he was executive director of commercial operations and marketing - will be at the forefront of a number of key accounts to help
-
Glenn Sblendorio to retire as president of The Medicines Company
He has over 20 years of experience in the pharmaceutical industry and prior to joining The Medicines Company held senior managing and financial positions at Eyetech Pharmaceuticals and MPM Capital Advisors. ... He currently serves as a director at Amicus
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
Pharma, Technology, and Healthcare in the New Normal
Brian Canestraro, General Manager at Intercept Pharmaceuticals, discusses leadership lessons and tips to the impact of the COVID-19 pandemic on the way that Pharma conducts clinical trials and interacts with
-
Pharma, Technology, and Healthcare in the New Normal
Brian Canestraro, General Manager at Intercept Pharmaceuticals, discusses a range of hot topics, from Brian’s leadership lessons and tips to the impact of the COVID-19 pandemic on the way
More from PMHub
Approximately 2 fully matching, plus 0 partially matching documents found.
Subscribe to our email news alerts
-
Senior Medical Writer
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
- MHRA to introduce new UK clinical trials framework
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- 2023 PM Society Awards – winners announced
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- WHO report highlights impact of COVID-19 pandemic on non-communicable diseases
- Critical success factors and the increasing value of rare disease clinical trials
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- Amgen gets block on sales of Repatha rival in Germany
- Congress is in session – how companies are boosting their impact and engagement
- The state of pharma customer experience
PMHub
Anthem PR
With a rare strength in media and influencer relations, Anthem’s award-winning team offers a fresh approach to health PR...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
